Sudarshan Pharma Industries Limited submitted its Unaudited Standalone & Consolidated Financial Results for the quarter ended 30th June 2026 pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Financial Performance (Standalone - ₹ in Lakhs)
Quarter Ended June 30, 2026:
- Revenue from operations: ₹16,566.03
- Other income: ₹135.38
- Total income: ₹16,701.41
- Total expenses: ₹15,887.66
- Profit before tax: ₹813.75
- Tax expense: ₹209.57
- Net profit for the period: ₹604.18
- Other comprehensive income: ₹0.38
- Total comprehensive income: ₹604.56
- Paid-up equity share capital: ₹2,496.59 (Face value ₹1 each)
- Basic EPS: ₹0.25
- Diluted EPS: ₹0.25
Comparative Figures:
- March 31, 2026: Net profit ₹954.28, Revenue ₹19,980.98
- June 30, 2025: Net profit ₹373.28, Revenue ₹14,231.10
- March 31, 2026 (Audited): Net profit ₹2,198.16, Revenue ₹66,749.85
Financial Performance (Consolidated - ₹ in Lakhs)
Quarter Ended June 30, 2026:
- Revenue from operations: ₹17,441.84
- Other income: ₹121.97
- Total income: ₹17,563.81
- Total expenses: ₹16,813.28
- Profit before tax: ₹750.53
- Tax expense: ₹189.59
- Net profit for the period: ₹560.94
- Share of non-controlling interest: ₹(24.58)
- Profit attributable to owners: ₹585.52
- Basic EPS: ₹0.23
- Diluted EPS: ₹0.23
Significant Developments
1. Palghar Unit Closure: During the quarter ended 30th June 2026, the Company decided to discontinue its manufacturing operations at the Palghar unit to rationalize fixed and operating costs and minimize further losses.
2. Dubai Court Award: The Company won an award from Dubai Court against Regans International DMCC and Nand Biharilal Chhabaria Biharilal Chunilal for UAE Dirham 40,30,934.00 (approx. ₹9,18,82,890) plus 5% annual interest. As of 30th June 2026, the Company received ₹4,68,00,535 (including interest), with balance to be received in future.
3. FCCB Issuance: The Board approved raising funds up to ₹1,500 Crores via FCCBs and other securities. On 15th May 2026, approved issuance of up to $20,000,000 8.00% senior unsecured FCCBs due 2029. On 21st May 2026, allotted $10,000,000 FCCBs convertible into equity shares at ₹30.19 per share. Proceeds received in tranches on 27th May 2026 ($900,000) and 4th June 2026 ($100,000).
4. Warrant Conversion: On 12th June 2026, the Warrants Committee allotted 90,00,000 equity shares at ₹16.98 each (including premium of ₹15.98) to promoters Mr. Hemal Mehta and Mr. Sachin Mehta upon conversion of warrants issued on 18th December 2024. Paid-up capital increased to ₹24,96,58,870 consisting of 24,96,58,870 equity shares of ₹1 each.
5. New Subsidiary: Effective 5th June 2026, incorporated "Sudarshan Industries Inc." as a wholly-owned subsidiary in USA. Company subscribed to 1,00,00,000 shares of USD0.00001 each (approx. ₹9,600) representing 100% paid-up capital.
Subsidiaries Included in Consolidation
The consolidated results include:
- Sudarshan Pharma Lifescience Private Limited
- Lifescience Chemical Private Limited
- Ratna Lifesciences Private Limited
- Sudarshan Maven Pharma Private Limited
- Ishwari Healthcare Private Limited
- Sudarshan Pharma Industries Private Limited, Singapore
- Cibachem General Trading LLC, Dubai (w.e.f 5th August 2025)
- Sudarshan Pharma Poland Limited Liability Company, Poland (w.e.f. 17th December 2025)
- Sudarshan Industries Inc, USA (w.e.f. 5th June 2026)
Auditor Review
NGST & Associates conducted limited review and issued unmodified reports for both standalone and consolidated results. The financial results of five subsidiaries (Singapore, Ishwari Healthcare, Dubai, Poland, and USA) were certified by their respective managements and not reviewed by auditors.